Anti-Von Willebrand Factor Antibody (Mouse Monoclonal antibody) General Information
Anti-Von Willebrand Factor Antibody
Reacts with: Human
Human Von Willebrand Factor
CHO cell-derived rhvWF (Catalog#10973-H08C)
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human von Willebrand factor (rhvWF; Catalog#10973-H08C; aa 1-2813; NP_000543.2). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Monoclonal Mouse IgG2a Clone #7G2B11C10
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Anti-Von Willebrand Factor Antibody (Mouse Monoclonal antibody) Validated Applications
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-Von Willebrand Factor Antibody Alternative Names
Anti-F8VWF Antibody;Anti-Von Willebrand Factor Antibody;Anti-VWD Antibody
Von Willebrand Factor Background Information
Von Willebrand Factor (VWF) is a multimeric glycoprotein involved in hemostasis in blood, binds receptors on the surface of platelets and in connective tissue, thereby mediating the adhesion of platelets to sites of vascular injury. From studies it appears that VWF protein uncoils under these circumstances, decelerating passing platelets. VWF protein is deficient or defective in von Willebrand disease (VWD) and is involved in a large number of other diseases, including thrombosis, thrombotic thrombocytopenic purpura, Stroke, Heyde's syndrome, possibly hemolytic-uremic syndrome and so on.
von Willebrand factor
Sadler JE. (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem, 67: 395-424.Batlle J, et al. (2009) Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 20(2):89-100.Sadler JE. (2009) von Willebrand factor assembly and secretion. J Thromb Haemost. 7 Suppl 1:24-7.Auton M, et al. (2010) The mechanism of VWF-mediated platelet GPIbalpha binding. Biophys J. 99(4):1192-201.Bowen DJ. (2010) Sugar targets VWF for the chop. Blood. 115(13):2565.Lpez JA, et al. (2010) VWF self-association: more bands for the buck. Blood. 116(19):3693-4.